Fig. 3From: Metabolomic profiles of metformin in breast cancer survivors: a pooled analysis of plasmas from two randomized placebo-controlled trialsPercent stacked bar-plots of participants with stable, increasing, or decreasing levels of metformin affected fatty acid data over time. Percent stacked bar-plots showing the percentage of participants with stable, increasing or decreasing values over time by treatment group for Percent 20:2n − 6 (left), Desaturation Index 18:1n − 9c/18:0 (center), and Long chain n-6 PUFA (right). Increasing levels of Percent 20:2n − 6 (Metformin vs. Placebo: 8% vs. 15%, P = 0.002) and decreasing levels of Desaturation Index 18:1n − 9c/18:0 (Metformin vs. Placebo: 6% vs. 18%, P = 0.001) were significantly more frequent in the placebo group. Conversely, Long chain n-6 PUFA decreased significantly more often in the metformin group (Metformin vs. Placebo: 11% vs. 5%, P = 0.03)Back to article page